Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$152.78 ▼ -20.67
(-11.92%)
MKT CAP: $10.13B • VOL: 3.40M
52W L $23 52W H $220
TWST // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$136.3M | -$220.8M | -$217.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$77.7M | -$208.7M | -$204.6M |
| EBITDA (Normalized) | -$113.9M | -$216.8M | -$217.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$47.6M | -$64.1M | -$142.5M |
| Capital Expenditures (CapEx) | $28.0M | $5.1M | $0 |
| Free Cash Flow (FCF) | -$75.6M | -$69.2M | -$142.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -27.6% | -45.0% | -4.5% |
| Cash & Short-Term Equivalents | $148.6M | $221.4M | — |
| Total Debt (Short + Long Term) | $81.9M | $68.7M | $1.48B |
| Total Stockholders' Equity | $456.1M | $455.9M | $3.04B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TWST.